We expect Vertex Pharmaceuticals Incorporated VRTX to surpass expectations when it reports first-quarter 2025 results on May ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Vertex Pharmaceuticals ( VRTX 2.72%) had a fine Tuesday on the stock exchange. The biotech 's shares closed the day nearly 3% ...

New non-opioid pain killer get FDA approval for acute pain. Patients are taking note. Also demonstrated efficacy, just not ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

Fye highlighted that Vertex’s 2025 revenue guide of $11.75 ... A quicker-than-expected ramp-up for Journavx Faster patient dosing for gene-editing therapy Casgevy. The former is shaping up ...

Vertex'w newest products fit the company's MO. Casgevy, approved in 2023, is a medicine for two rare, life-threatening blood ...

Casgevy and Journavx are poised to become significant growth drivers for Vertex Pharmaceuticals in the coming years, marking pivotal steps in the company's push to diversify its portfolio.

VX-548, also known as suzetrigine, brand name Journavx, is the key asset in the pain program at Vertex. It was approved in moderate-to-severe acute pain on January 30, 2025. It is now running a ...

Vertex is appealing simply by virtue of its ... as the apparent robust demand for Journavx indicates. I think this stock is well worth a look as a somewhat offbeat way to play the biotech and ...